About Aurion Biotech
Aurion Biotech is a company based in Seattle (United States) founded in 2021 was acquired by Alcon in March 2025. It operates as a HealthTech. Aurion Biotech has raised $120 million across 1 funding round from investors including Alcon, KKR and Falcon-Vision. Aurion Biotech offers products and services including Cell Therapy for Corneal Endothelial Disease. Aurion Biotech operates in a competitive market with competitors including ViaCyte, Capricor Therapeutics, Neurona Therapeutics, EpiBone and Gamida Cell, among others.
- Headquarter Seattle, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aurion Biotech Japan, Llc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aurion Biotech
Aurion Biotech offers a comprehensive portfolio of products and services, including Cell Therapy for Corneal Endothelial Disease.
Cell therapy is developed for corneal endothelial diseases.
People of Aurion Biotech
Unlock access to complete
Unlock access to complete
Funding Insights of Aurion Biotech
Aurion Biotech has successfully raised a total of $120M through 1 strategic funding round. The most recent funding activity was a Series C round of $120 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aurion Biotech
Aurion Biotech has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Alcon, KKR and Falcon-Vision.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Petrichor is engaged in supporting healthcare innovation through investments.
|
Locked | Locked | Locked | |
|
Flying L Partners is focused on ophthalmic sector investments.
|
Locked | Locked | Locked |
Investor details for Aurion Biotech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aurion Biotech
Investment portfolio details for Aurion Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aurion Biotech
Detailed financials for Aurion Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aurion Biotech Comparisons
Peer comparison for Aurion Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aurion Biotech
Aurion Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ViaCyte, Capricor Therapeutics, Neurona Therapeutics, EpiBone and Gamida Cell, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cell therapy for diabetes is developed from stem cells.
|
|
| Locked | Locked | Locked |
Regenerative medicine for cardiovascular disorders is developed using cell-based platforms.
|
|
| Locked | Locked | Locked |
Cell-based therapies are developed for intractable neurological diseases.
|
|
| Locked | Locked | Locked |
Developer of stem cells to regrow damaged bones
|
|
| Locked | Locked | Locked |
Cell therapies for cancer and serious diseases are developed.
|
|
| Locked | Locked | Locked |
Tissue engineering company utilizing a proprietary stem technology to treat degenerative disc disease.
|
Detailed competitors of Aurion Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aurion Biotech
Complete news archive for Aurion Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aurion Biotech
Aurion Biotech was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Aurion Biotech is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Greg Kunst is the current CEO of Aurion Biotech.
Aurion Biotech is a funded company, having raised a total of $120M across 1 funding round to date.
Aurion Biotech is engaged in the development of innovative therapies aimed at restoring vision. The company operates as a clinical-stage biotech entity with a primary focus on ocular diseases, particularly corneal endothelial dystrophies. A patented cell therapy treatment is being developed as their first candidate to address these conditions. Their work spans across the healthcare sector, emphasizing accessible and effective solutions for patients worldwide.
Aurion Biotech's top competitors include EpiBone, Neurona Therapeutics and Gamida Cell.
Aurion Biotech offers Cell Therapy for Corneal Endothelial Disease.
Aurion Biotech has 7 investors. Key investors include Alcon, KKR, Falcon-Vision, Deerfield, and Petrichor.